Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

11/8/24 10:34:33 AM ET

$ALNY

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALNY alert in real time by email

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 13 )^*

Alnylam Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

02043Q107

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)

CUSIP No.

02043Q107

1.	NAMES OF REPORTING PERSONS Wellington Management Group LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,902,617
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	5,018,779
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,018,779
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.91%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

02043Q107

1.	NAMES OF REPORTING PERSONS Wellington Group Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,902,617
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	5,018,779
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,018,779
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.91%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

02043Q107

1.	NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	4,902,617
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	5,018,779
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,018,779
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.91%
12.	TYPE OF REPORTING PERSON HC

Item 1.
	(a)	Name of Issuer Alnylam Pharmaceuticals, Inc.
	(b)	Address of Issuer's Principal Executive Offices 675 West Kendall Street Cambridge, MA 02142
Item 2.
	(a)	Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP
	(b)	Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210
	(c)	Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 02043Q107
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[ ]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[X]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
		If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		See the responses to Item 9 on the attached cover pages.
	(b)	Percent of Class:
		See the responses to Item 11 on the attached cover pages.
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	0
		(ii)	shared power to vote or to direct the vote	See the responses to Item 6 on the attached cover pages.
		(iii)	sole power to dispose or to direct the disposition of	0
		(iv)	shared power to dispose or to direct the disposition of	See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
	Wellington Group Holdings LLP – HC
	Wellington Investment Advisors LLP – HC
	Wellington Management Global Holdings, Ltd. - HC
	One or more of the following investment advisers (the “Wellington Investment Advisers”):
	Wellington Management Company LLP – IA
	Wellington Management Canada LLC – IA
	Wellington Management Singapore Pte Ltd – IA
	Wellington Management Hong Kong Ltd – IA
	Wellington Management International Ltd – IA
	Wellington Management Japan Pte Ltd – IA
	Wellington Management Australia Pty Ltd - IA
	The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group. Not Applicable.
Item 9.	Notice of Dissolution of Group. Not Applicable.
Item 10.	Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	By: Wellington Management Group LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Group Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Investment Advisors Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

Get the next $ALNY alert in real time by email

Recent Analyst Ratings for

$ALNY

Date	Price Target	Rating	Analyst
3/31/2025	$353.00	Buy	Redburn Atlantic
3/24/2025	$280.00 → $328.00	Neutral → Overweight	Analyst
11/12/2024		Peer Perform → Underperform	Wolfe Research
10/16/2024		Sector Outperform	Scotiabank
8/16/2024	$198.00 → $370.00	Neutral → Buy	Goldman
2/16/2024	$173.00	Buy → Neutral	Goldman
2/15/2024		Peer Perform	Wolfe Research
12/8/2023	$171.00	Equal Weight	Wells Fargo

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 13 )*

SIGNATURE

Chat with this insight

Recent Analyst Ratings for $ALNY

$ALNY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

$ALNY Financials

Live finance-specific insights

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

$ALNY Leadership Updates

Live Leadership Updates

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

$ALNY Large Ownership Changes

This live feed shows all institutional transactions in real time.